These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 18425336

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
    Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA, Gynecologic Oncology Group Phase III Trial.
    J Clin Oncol; 2008 Jul 20; 26(21):3598-606. PubMed ID: 18640939
    [Abstract] [Full Text] [Related]

  • 63. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
    Tsuji A, Shima Y, Morita S, Uchida M, Okamoto K, Morita M, Horimi T, Shirasaka T.
    Anticancer Res; 2008 Jul 20; 28(2B):1433-8. PubMed ID: 18505092
    [Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
    Marsh S, Paul J, King CR, Gifford G, McLeod HL, Brown R.
    J Clin Oncol; 2007 Oct 10; 25(29):4528-35. PubMed ID: 17925548
    [Abstract] [Full Text] [Related]

  • 66. Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.
    Sun JM, Ahn MJ, Park MJ, Lee HY, Ahn JS, Lee S, Kang G, Han J, Son YI, Baek CH, Ahn YC, Park K.
    Int J Radiat Oncol Biol Phys; 2011 Jul 01; 80(3):655-60. PubMed ID: 21621119
    [Abstract] [Full Text] [Related]

  • 67. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM, Moore KN, Myers TK, Lanneau GS, McMeekin DS, Walker JL, Gold MA.
    Gynecol Oncol; 2009 Feb 01; 112(2):337-41. PubMed ID: 19041126
    [Abstract] [Full Text] [Related]

  • 68. Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
    Nikitas N, Karadimou A, Tsitoura E, Soupos N, Tsiatas M, Karavasilis V, Pectasides D, Pavlidis N, Chrisofos M, Adamakis I, Murray S, Fountzilas G, Dimopoulos MA, Bamias A.
    Pharmacogenomics; 2012 Nov 01; 13(14):1595-607. PubMed ID: 23148636
    [Abstract] [Full Text] [Related]

  • 69. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations.
    Ganzinelli M, Mariani P, Cattaneo D, Fossati R, Fruscio R, Corso S, Ricci F, Broggini M, Damia G.
    Eur J Cancer; 2011 May 01; 47(7):1086-94. PubMed ID: 21216588
    [Abstract] [Full Text] [Related]

  • 70. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
    Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J.
    J Clin Oncol; 2009 Jun 10; 27(17):2863-73. PubMed ID: 19332728
    [Abstract] [Full Text] [Related]

  • 71. [Analysis of patients with locally advanced gastric cancer undergoing gastrectomy after pre-operative chemotherapy including S-1].
    Kinouchi M, Shibata C, Miura K, Okabe M, Andou T, Kakyou M, Saijou F, Haneda S, Ogawa H, Unno M, Sasaki I.
    Gan To Kagaku Ryoho; 2009 Sep 10; 36(9):1481-4. PubMed ID: 19755816
    [Abstract] [Full Text] [Related]

  • 72. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E, Rosell R.
    Expert Rev Mol Diagn; 2007 May 10; 7(3):261-8. PubMed ID: 17489733
    [Abstract] [Full Text] [Related]

  • 73. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
    Sugimoto N, Narahara H, Sakai D, Yamamoto S, Fumoto S, Yagi T, Imamura F, Iishi H, Tatsuta M.
    Gan To Kagaku Ryoho; 2009 Mar 10; 36(3):417-24. PubMed ID: 19295265
    [Abstract] [Full Text] [Related]

  • 74. [S-1/CDDP combined neoadjuvant chemotherapy and surgical resection for advanced gastric cancer. Analysis of 12 patients with lymph node metastasis in Saitama Red Cross Hospital].
    Nakamura Y, Nakagawa K, Fujita M, Moriya T, Miyazaki M.
    Gan To Kagaku Ryoho; 2009 Aug 10; 36(8):1287-91. PubMed ID: 19692767
    [Abstract] [Full Text] [Related]

  • 75. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.
    Biankin AV, Kench JG, Colvin EK, Segara D, Scarlett CJ, Nguyen NQ, Chang DK, Morey AL, Lee CS, Pinese M, Kuo SC, Susanto JM, Cosman PH, Lindeman GJ, Visvader JE, Nguyen TV, Merrett ND, Warusavitarne J, Musgrove EA, Henshall SM, Sutherland RL, NSW Pancreatic Cancer Network.
    Gastroenterology; 2009 Aug 10; 137(2):558-68, 568.e1-11. PubMed ID: 19376121
    [Abstract] [Full Text] [Related]

  • 76. ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer.
    Xu ZC, Cai HZ, Li X, Xu WZ, Xu T, Yu B, Zou Q, Xu L.
    Genet Mol Res; 2016 May 23; 15(2):. PubMed ID: 27323074
    [Abstract] [Full Text] [Related]

  • 77. ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation.
    De Castro G, Pasini FS, Siqueira SA, Ferraz AR, Villar RC, Snitcovsky IM, Federico MH.
    Oncol Rep; 2011 Mar 23; 25(3):693-9. PubMed ID: 21206986
    [Abstract] [Full Text] [Related]

  • 78. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
    Li S, Wu J, Chen Y, Tang W, Peng Q, Deng Y, Xie L, Wang J, Huang S, Li R, Qin X, Zhao J.
    Anticancer Drugs; 2014 Jan 23; 25(1):106-14. PubMed ID: 24025563
    [Abstract] [Full Text] [Related]

  • 79. The C19007T polymorphism of ERCC1 and its correlation with the risk of epithelial ovarian and endometrial cancer in Korean women. A case control study.
    Jo H, Kang S, Kim SI, Kim JW, Park NH, Song YS, Park SY, Kang SB, Lee HP.
    Gynecol Obstet Invest; 2007 Jan 23; 64(2):84-8. PubMed ID: 17314486
    [Abstract] [Full Text] [Related]

  • 80. Polymorphisms in ERCC1 and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.
    Wang SL, Zhao H, Zhou B, Chen YL, Zou Y, Zhu XF, Li QS, Han MZ, Yang RC, Han ZC.
    Leuk Res; 2006 Nov 23; 30(11):1341-5. PubMed ID: 16723154
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.